Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
NCT00888186 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2009-04-27
Summary
The purpose of this study is to study different kinds of dyskinesias in advanced Parkinson's disease appearing at different levels of levodopa infusion dose. The hypothesis is that different dyskinesias (dystonia, chorea) correlate to different levels of levodopa concentrations, as detected in plasma.
Conditions
- Parkinson Disease
- Dyskinesias
Interventions
- DRUG
-
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
Sponsors & Collaborators
-
Swedish Parkinson's Disease Foundation
collaborator UNKNOWN -
Swedish Society for Medical Research
collaborator OTHER -
Uppsala University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 30 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-02-29
- Primary Completion
- 2008-05-31
- Completion
- 2008-05-31
Countries
- Sweden
Study Locations
More Related Trials
-
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
NCT04064294 ·Status: COMPLETED
-
Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
NCT00906828 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
NCT00888004 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Levodopa for the Diagnosis of Parkinson's Disease
NCT00001928 ·Status: COMPLETED
-
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
NCT00845000 ·Status: COMPLETED ·Phase: PHASE1
-
Vigor and the LDR in Parkinson Disease
NCT04821830 ·Status: COMPLETED ·Phase: PHASE4
-
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
NCT01336088 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
NCT04380142 ·Status: COMPLETED ·Phase: PHASE3
-
Dyskinesia in Parkinson's Disease (Study P04501)
NCT00406029 ·Status: COMPLETED ·Phase: PHASE2
-
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
NCT00957918 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
NCT05471609 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
NCT00099268 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
NCT01294800 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
NCT04778176 ·Status: COMPLETED ·Phase: PHASE2
-
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
NCT00642356 ·Status: TERMINATED ·Phase: PHASE4
-
Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)
NCT01500707 ·Status: WITHDRAWN ·Phase: PHASE1
-
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
NCT04157933 ·Status: COMPLETED ·Phase: PHASE1
-
EMD 128130 for the Treatment of Parkinson's Disease
NCT00009048 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
NCT02486432 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
NCT00558337 ·Status: COMPLETED ·Phase: PHASE2
-
Stalevo in Early Wearing-Off Patients
NCT00125567 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00357994 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
NCT02782481 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
NCT06055985 ·Status: COMPLETED ·Phase: PHASE2
-
Dopamine Effect on Inhibitory Control
NCT03665493 ·Status: COMPLETED ·Phase: NA